"Therefore, this study confirms the clinical utility of RV(+) in the pediatric setting."

"Similar PPA and NPA were observed for self- and HCP-collected specimens as well as visually- and analyzer-interpreted tests. The equivalence in performance supports the use of expanded collection and testing methods."

"In patients with suspected influenza in the emergency department, although rapid NAAT [ID NOW Influenza A&B, Abbott] and RAT [BD Veritor System for Rapid Detection of Flu A + B, BD] demonstrated good agreement, the cases that tested positive by the rapid NAAT but negative by the RAT were significantly more frequent. This suggests that rapid NAAT may be a more suitable diagnostic tool in the emergency department, as rapid NAAT can help avoid false negatives, enable timely antiviral treatment, and improve clinical decision-making within the critical treatment window."

"Compared to antigen-based lateral flow assays [BD Veritor™ Plus System, Sofia® Strep A+ Fluorescent Immunoassay, and Sekisui Diagnostic OSOM® Strep A test for GAS detection], the molecular ID Now Strep A 2 assay demonstrated a lower LoD, which translates into higher sensitivity. In a clinical setting, this could enable detection of samples with a lower bacterial load that could be missed by low-sensitivity LFAs."

"Overall sensitivities of three SARS-CoV-2 Ag-RDTs [BD-Veritor System (Becton Dickinson), PanBio (Abbott), or SD-Biosensor (Roche Diagnostics)] were 69–75%, increasing to greater than or equal to 86% above a viral load cut-off. The decreased sensitivity among asymptomatic participants and high positivity rate during follow-up in false-negative Ag-RDT participants emphasise the need for education of the public about the importance of re-testing after an initial negative Ag-RDT should symptoms develop. For SD-Biosensor, the diagnostic accuracy with OP-N and deep nasopharyngeal sampling was similar; adopting the more convenient sampling method might reduce the threshold for professional testing."

This study confirms that NAATs (Aptima and cobas) are highly sensitive and consistent, whereas rapid antigen tests (Veritor and BinaxNOW) detect fewer than 50% of positive cases. While antigen tests maintain 100% specificity, their sensitivity depends heavily on viral load; they perform well at low Ct values (<20–25) but fail frequently as Ct values increase. Consequently, antigen assays may miss infections in patients with lower levels of viral shedding.

The Veritor test met EUA criteria with a positive percent agreement of eighty percent or greater and AUC values of zero point nine zero or higher within zero to six days of symptom onset. Outperforming the Sofia 2 in positive detections, this fifteen-minute nasal swab test offers a fast, safe, and effective diagnostic solution compared to labor-intensive methods. Its performance in clinically relevant populations makes it an essential alternative to PCR in decentralized settings where rapid turnaround is critical for patient management.

The study compared the ID NOW (a rapid NAAT) with three digital LFIAs: BD Veritor Plus, STANDARD F, and ichroma TRIAS. While ID NOW demonstrated superior sensitivity, the digital LFIAs - particularly the ichroma TRIAS - proved to be efficient, high-throughput alternatives suitable for large-scale clinical testing.

"The careUS Strep A Plus is a useful test that showed highly comparable results with those of the culture test and superior performances among the three RADTs [SD Bioline, BD Veritor]. The use of RADTs should be encouraged to provide acceptable and fast results using simple equipment."

The evaluation of the BinaxNow, SD Bioline, BD Veritor, and Humasis rapid antigen tests against real-time RT-PCR shows that while these tools offer high specificity, their moderate sensitivity (61.3%–67.5%) limits their diagnostic power. Consequently, these rapid assays are useful for initial screening, but negative results should be confirmed via PCR to ensure accurate patient management.

The BD Veritor™ System offers superior sensitivity compared to traditional assays like BinaxNOW® and SD Influenza Ag, particularly for influenza A, while maintaining 100% specificity. By utilizing a digital reader, it effectively detects lower viral loads that these visual tests often miss. Overall, it provides a faster, more reliable point-of-care solution for early influenza management and infection control.

"In summary, the BD Veritor System for Flu A+B was observed to be more sensitive than the Alere BinaxNOW influenza A&B card for detection of influenza A and B viruses from respiratory specimens. In addition, an objective read by the BD Veritor System reader potentially minimizes operator errors, particularly with interpretation of specimens with low viral titers, and this may represent a significant improvement over traditional lateral flow antigen tests used for influenza diagnosis."